Submitted for Publication: April 9, 2013; final revision received and accepted September 9, 2014.
Published Online: March 12, 2014. doi:10.1001/jamapsychiatry.2013.4091.
Study concept and design: Lerman, Loughead, Ruparel, Yang, Stein.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Lerman, Gu, Stein.
Critical revision of the manuscript for important intellectual content: Gu, Loughead, Ruparel, Yang, Stein.
Statistical analysis: Gu, Ruparel, Yang, Stein.
Obtained funding: Lerman, Loughead, Stein.
Administrative, technical, or material support: Gu, Loughead, Yang, Stein.
Study supervision: Loughead, Yang, Stein.
Conflict of Interest Disclosures: Dr Lerman has received research funding from Pfizer independent of this research project. No other disclosures were reported.
Funding/Support: This study was supported by grants P50 CA143187 and R03 DA027438 (Dr Lerman), the Intramural Research Program of the National Institute on Drug Abuse (Dr Stein), and the Commonwealth of Pennsylvania Department of Health.
Role of the Sponsor: The funding sources had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
Additional Contributions: James Loughead, PhD, Ruben Gur, PhD, and E. Paul Wiley, PhD, assisted in the design of the original study. Leah La Prate, Mary Falcone, PhD, Christopher Jepson, PhD, and Susan Ware, BA, contributed data set creation and data management.